医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar Candidate SCB-808 in China

2018年08月01日 PM10:00
このエントリーをはてなブックマークに追加


 

CHENGDU, China

Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase I trial of SCB-808, a proposed biosimilar of Enbrel® (etanercept) being developed in the prefilled syringe formulation for the treatment of rheumatoid arthritis and other autoimmune diseases.

“This milestone marks Clover’s second biologic product to initiate human clinical trials in as many months. Now with clinical trials actively enrolling patients in multiple countries, Clover has demonstrated its ability to execute on its goals across multiple functional areas,” said Joshua Liang, Chief Strategy Officer and Board Director at Clover. “We look forward to further advancing our deep pipeline of promising biological candidates in the months ahead.”

The Phase I trial in China is designed to assess the pharmacokinetics, safety and immunogenicity of subcutaneously administered SCB-808 and originator drug Enbrel® in healthy volunteers.

“Having compared SCB-808 to both Enbrel® and other Chinese etanercept biosimilars in preclinical studies, we believe that our superior biomanufacturing process, biosimilarity to Enbrel® and convenient ready-for-injection prefilled syringe formulation will allow us to have significant commercial advantages once SCB-808 is brought to the market,” said Dr. Peng Liang, co-founder, Chairman and President of Clover. “Importantly, we hope that SCB-808 will meaningfully impact the lives of many patients, and the initiation of this Phase I trial brings us one step closer to this goal.”

Currently available etanercept biosimilars in China were all developed and approved prior to the implementation of the CFDA’s Technical Guideline for Development and Evaluation of Biosimilars and were not compared to the originator drug Enbrel® in clinical trials to demonstrate their bioequivalence. Furthermore, they are only approved in the lyophilized powder formulation, which must be reconstituted typically by trained medical personnel before being subcutaneously injected into patients. SCB-808 is being developed in the prefilled syringe formulation, which is ready-for-injection and can potentially be self-administered by patients in the convenience of their own homes. Thus, in the Western world, ready-for-injection formulations constitute the overwhelming majority of Enbrel® prescriptions. As such, Clover’s SCB-808 has the potential to address the unmet needs of Chinese patients for this class of drugs.

About Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars. For more information, please visit our website: www.cloverbiopharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180801005387/en/

CONTACT

Clover Biopharmaceuticals
Joshua Liang, +86 028-85336966
joshua.liang@cloverbiopharma.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc